RJA
VANI icon

Raymond James & Associates’s Vivani Medical VANI Stock Holding History

Raymond James & Associates’s Portfolio VANI Stock Details VANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-620
Closed -$18K – 3535
2017
Q3 		$18K Buy
+620
New +$17.3K ﹤0.01% 3321

Other funds holding VANI

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return

Raymond James & Associates's VANI Position: Q4 2017 in Review

Raymond James & Associates sold out of Vivani Medical (VANI) in Q4 2017, closing a stake of 620 shares — an estimated $18K sold.

Raymond James & Associates first reported a position in VANI in Q3 2017 and held it in 1 quarter. The position peaked at $18K in Q3 2017. 43 funds tracked by Wall St. Rank hold VANI as of Q4 2017.

  • Raymond James & Associates reported no remaining Vivani Medical position as of Q4 2017 after selling out during the quarter.
  • Raymond James & Associates sold 620 Vivani Medical shares in Q4 2017, an estimated $18K.
  • Raymond James & Associates first reported a position in Vivani Medical in Q3 2017 and held it in 1 quarter.
  • Raymond James & Associates's Vivani Medical position peaked at $18K in Q3 2017.
  • 43 funds tracked by Wall St. Rank held Vivani Medical as of Q4 2017.

Based on Raymond James & Associates's 13F filing for Q4 2017, filed 14 Feb 2018.